# Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

> **NCT05565794** · PHASE2 · TERMINATED · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 2 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- FGFR2 Gene Mutation
- FGFR2 Gene Rearrangement
- FGFR2 Gene Translocation

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT05565794
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-11
- **Primary completion:** 2025-03-27
- **Final completion:** 2025-03-27
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565794, "Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05565794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*